StoxTorrent Pharmaceuticals vs Cipla: share price & financials comparison
NSE: TORNTPHARM vs CIPLA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Torrent Pharmaceuticals vs Cipla at a glance
Torrent Pharmaceuticals (TORNTPHARM) has a market capitalisation of ₹1,77,628 Cr, against ₹1,12,437 Cr for Cipla (CIPLA). Over the past year Torrent Pharmaceuticals has returned +30.6%, compared with -7.4% for Cipla. On valuation, Cipla trades at a lower P/E of 38.8 versus 83.6. Torrent Pharmaceuticals earns a higher return on equity (11.6% vs 8.2%). Torrent Pharmaceuticals comes out ahead on profitability, growth, momentum and technicals. Cipla comes out ahead on size, valuation and financial health. Across the scored metrics below, Torrent Pharmaceuticals leads on 12 and Cipla on 6. On StoxGud's 10-point checklist, Torrent Pharmaceuticals scores 7/10 and Cipla scores 7/10.
| Metric | Torrent Pharmaceuticals | Cipla |
|---|---|---|
| Size | ||
| Market cap | ₹1,77,628 Cr | ₹1,12,437 Cr |
| Revenue (latest FY) | ₹13,980 Cr | ₹28,163 Cr |
| Net profit (latest FY) | ₹2,163 Cr | ₹3,879 Cr |
| Valuation | ||
| P/E | 83.6 | 38.8 |
| P/B | 9.67 | 3.18 |
| Dividend yield | 0.73% | 1.15% |
| Profitability | ||
| Return on equity | 11.6% | 8.2% |
| Net profit margin | 12.2% | 10.3% |
| Operating margin | 33.2% | 17.0% |
| Growth | ||
| Revenue growth (YoY) | +50.8% | -2.4% |
| Net profit growth (YoY) | -9.6% | -35.1% |
| Revenue CAGR (multi-year) | +11.8% | +8.0% |
| Financial health | ||
| Debt to equity | 0.76 | 0.01 |
| Momentum | ||
| 1-month return | +0.6% | +4.7% |
| 1-year return | +30.6% | -7.4% |
| 3-year CAGR | +31.2% | +3.9% |
| 5-year CAGR | +27.3% | +8.2% |
| 10-year CAGR | +22.2% | +9.7% |
| Distance from 52W high | -8.8% | -9.4% |
| Technicals | ||
| RSI (14) | 62 | 68 |
| Price vs 200-day avg | +2.8% | +2.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Torrent Pharmaceuticals | Cipla |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Torrent Pharmaceuticals or Cipla?
Torrent Pharmaceuticals has a market cap of ₹1,77,628 Cr and Cipla has a market cap of ₹1,12,437 Cr as of 13 Nov 2026.
Which has a lower P/E, Torrent Pharmaceuticals or Cipla?
Cipla has the lower P/E: Torrent Pharmaceuticals trades at 83.6 and Cipla at 38.8.
Which gave better returns in the last year, Torrent Pharmaceuticals or Cipla?
Torrent Pharmaceuticals did better: Torrent Pharmaceuticals returned +30.6% and Cipla returned -7.4% over one year.
What is the difference between Torrent Pharmaceuticals and Cipla?
Both are NSE-listed companies in Healthcare. Torrent Pharmaceuticals is about 1.6 times the size of Cipla by market cap. In the latest financial year Torrent Pharmaceuticals reported revenue of ₹13,980 Cr and Cipla ₹28,163 Cr. Operating margin is 33.2% for Torrent Pharmaceuticals and 17.0% for Cipla. Debt to equity is 0.76 for Torrent Pharmaceuticals and 0.01 for Cipla.
Which is better, Torrent Pharmaceuticals or Cipla?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Torrent Pharmaceuticals leads on 12 and Cipla on 6. Torrent Pharmaceuticals is ahead on profitability, growth, momentum and technicals. Cipla is ahead on size, valuation and financial health. On StoxGud's rules-based checklist Torrent Pharmaceuticals scores 7/10 and Cipla scores 7/10. This is information, not advice: consult a SEBI-registered adviser before investing.